Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...

In a report released yesterday, Vikram Purohit from Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), ...

The Axsome drug, Auvelity, is already approved as a treatment for major depressive disorder. The preliminary results announced Monday are from two tests of the pill as a treatment for Alzheimer ...

For deeper insights into Axsome's valuation and growth prospects, including additional ProTips and comprehensive financial analysis, check out the detailed Pro Research Report available on ...

“We also look to carry our commercial momentum into 2025 with continued growth for Auvelity and Sunosi, and are making active launch preparations for AXS-07 for the acute treatment of ...

Ami Fadia, an analyst from Needham, maintained the Buy rating on Axsome Therapeutics (AXSM – Research Report). The associated price target ...

For deeper insights into Axsome's valuation and growth prospects, including additional ProTips and comprehensive financial analysis, check out the detailed Pro Research Report available ... results ...